Skip to content
Screener

Denali Therapeutics Inc. DNLI Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
893.7M-0.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
106M-2.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
101.9M+3.5%
uniQure logo
uniQureQURE
66.2M+20.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
82.5M-4.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
81.6M+27.8%

Other financials

Income statement

See full
Revenue$3.6M—
Gross profit$3.5M—
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0×0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Numerator:
Net loss$(127,553)$(124,119)$(256,000)$(257,089)
Denominator:
Weighted average number of:
Common stock shares outstanding158,982,722145,403,782158,645,833145,290,503
Pre-funded warrants28,331,77926,046,06528,331,77926,046,065
Total187,314,501171,449,847186,977,612171,336,568
Net loss per share$(0.68)$(0.72)$(1.37)$(1.50)

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s shares (diluted)?
Denali Therapeutics Inc. (DNLI) reported shares (diluted) of 187.3M in Q2 2026.
How has Denali Therapeutics Inc.'s shares (diluted) changed year-over-year?
Denali Therapeutics Inc.'s shares (diluted) increased by 9.3% year-over-year, from 171.4M to 187.3M.
What is the long-term trend for Denali Therapeutics Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s shares (diluted) has grown at a 9.1% compound annual growth rate (CAGR), from 485.4M to 687.7M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Denali Therapeutics Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude